Adicet Bio (NASDAQ:ACET) Upgraded at Truist Financial

Adicet Bio (NASDAQ:ACET) was upgraded by stock analysts at Truist Financial to a “strong-buy” rating in a research note issued to investors on Wednesday,Zacks.com reports.

ACET has been the topic of a number of other research reports. Canaccord Genuity Group set a $18.00 target price on Adicet Bio and gave the company a “buy” rating in a research note on Tuesday, January 6th. HC Wainwright dropped their price target on Adicet Bio from $50.00 to $27.00 and set a “buy” rating for the company in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adicet Bio in a report on Tuesday, January 27th. Finally, Guggenheim reduced their price objective on Adicet Bio from $128.00 to $100.00 and set a “buy” rating on the stock in a research report on Friday, March 13th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $56.25.

Adicet Bio Price Performance

ACET stock opened at $6.81 on Wednesday. The firm has a 50 day simple moving average of $7.43 and a two-hundred day simple moving average of $9.80. The stock has a market cap of $65.38 million, a PE ratio of -0.38 and a beta of 1.56. Adicet Bio has a one year low of $6.41 and a one year high of $17.44.

Adicet Bio (NASDAQ:ACET) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($2.94) earnings per share for the quarter, beating the consensus estimate of ($3.23) by $0.29. On average, research analysts expect that Adicet Bio will post -1.39 EPS for the current fiscal year.

Hedge Funds Weigh In On Adicet Bio

Large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its stake in Adicet Bio by 1.7% in the first quarter. Goldman Sachs Group Inc. now owns 3,816,556 shares of the company’s stock worth $2,882,000 after purchasing an additional 63,691 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of Adicet Bio by 66.6% during the third quarter. Two Sigma Investments LP now owns 854,568 shares of the company’s stock valued at $692,000 after buying an additional 341,761 shares during the last quarter. Franklin Resources Inc. purchased a new position in shares of Adicet Bio in the fourth quarter worth about $5,276,000. Citadel Advisors LLC increased its holdings in shares of Adicet Bio by 19.8% in the third quarter. Citadel Advisors LLC now owns 583,948 shares of the company’s stock worth $473,000 after buying an additional 96,342 shares during the period. Finally, Wealthedge Investment Advisors LLC lifted its stake in shares of Adicet Bio by 37.4% in the 2nd quarter. Wealthedge Investment Advisors LLC now owns 313,108 shares of the company’s stock valued at $191,000 after acquiring an additional 85,307 shares during the last quarter. Hedge funds and other institutional investors own 83.89% of the company’s stock.

Adicet Bio News Roundup

Here are the key news stories impacting Adicet Bio this week:

• Positive Sentiment: HC Wainwright raised near-term and full-year 2026 EPS forecasts (Q1–Q4 and FY), trimming projected losses (e.g., Q1 est. now ($2.80) vs prior ($2.91); FY2026 now ($11.58) vs ($12.17)) and reiterated a “Buy” rating with a $27 price target — signals improved analyst sentiment and a large implied upside versus the current share price. MarketBeat HC Wainwright Coverage
• Positive Sentiment: Zacks upgraded ACET to a Zacks Rank #2 (Buy), citing improving earnings prospects — upgrades from recognized research services can attract buying interest and short-term momentum. Adicet Bio (ACET) Upgraded to Buy: Here’s Why
• Neutral Sentiment: Reported short-interest data for March shows anomalous “0 shares” and NaN changes across multiple filings — the numbers appear unreliable or misreported, so there is no clear evidence of elevated short pressure based on the available data. (Monitor future filings for corrected short-interest figures.)
• Negative Sentiment: An AmericanBankingNews headline framed HC Wainwright’s coverage as a “pessimistic forecast” for ACET stock price — conflicting media spin can add volatility even when analyst estimates are being trimmed toward smaller losses. HC Wainwright Issues Pessimistic Forecast for Adicet Bio (NASDAQ:ACET) Stock Price

About Adicet Bio

Adicet Bio, Inc (NASDAQ: ACET) is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company’s proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet’s lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.